Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts
Top Cited Papers
- 7 June 2016
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 65 (4), 734-740
- https://doi.org/10.1016/j.jhep.2016.05.045
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized studyHepatology, 2016
- Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patientseLife, 2015
- Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trialsHepatology, 2015
- LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*Journal of Hepatology, 2015
- Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)Hepatology, 2015
- Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcomeJournal of Clinical Investigation, 2014
- Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular CarcinomaAnnals of Internal Medicine, 2013
- Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference reportThe Lancet Oncology, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Management of Hepatocellular Carcinoma *Hepatology, 2005